Trump Signs Executive Order Downgrading Marijuana to Schedule III Drug
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 28 2025
0mins
Source: Fool
- Strong Policy Signal: President Trump signed an executive order downgrading marijuana from Schedule I to Schedule III, which, while not fully legalizing it, is seen as a strong signal that significant changes in cannabis policy may be imminent, potentially paving the way for full legalization.
- Medicare Coverage Prospects: The president confirmed that Medicare may begin covering various CBD treatment costs, which will create new market opportunities for the cannabis industry and further promote the acceptance and use of medical marijuana.
- Increased Market Support: With 40 states allowing medical marijuana use and nearly two-thirds of adults supporting full legalization, there is strong voter backing expected to drive growth and profitability for cannabis businesses.
- Tax Deduction Potential: Downgrading marijuana to Schedule III will allow businesses to benefit from significant tax deductions, reducing operational costs and likely leading to lower retail prices, which will stimulate demand and increase future revenues and profits.
Analyst Views on TLRY
Wall Street analysts forecast TLRY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLRY is 9.57 USD with a low forecast of 8.50 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 8.730
Low
8.50
Averages
9.57
High
10.00
Current: 8.730
Low
8.50
Averages
9.57
High
10.00
About TLRY
Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis operations, Distribution business, Beverage alcohol business and Wellness business. The Cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis. The Beverage alcohol operations, which encompasses the production, marketing and sale of beverage alcohol products. The Distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers. The Wellness products, which encompasses hemp foods and cannabidiol (CBD) products. The Company offers a portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Hop Valley, Revolver, Bake Sale, XMG, Mollo, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
